HGH Fragment 176-191 vs Tesamorelin

Written by the Pure Peptides editorial team

Reviewed by Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer · Reviewed

Published · Updated · 7 references

HGH Fragment 176-191 and Tesamorelin are different molecules: HGH Fragment 176-191 is a 16-residue fragment of human growth hormone, and Tesamorelin is a 44-residue analog of human growth hormone-releasing hormone.

HGH Fragment 176-191

HGH Fragment 176-191

View HGH Fragment 176-191
vs
Tesamorelin

Tesamorelin

View Tesamorelin

Structure at a glance

Each chain as stored in the product database, one box per residue. The two are drawn separately; no alignment between them is implied.

HGH Fragment 176-191 · 16 residues

Tesamorelin · 44 residues

Hex: N-terminal trans-3-hexenoyl group. NH2: C-terminal amide. Letters are one-letter amino acid codes.

Chain length
HGH Fragment 176-19116 residues
Tesamorelin44 residues
Molecular weight
HGH Fragment 176-1911,799.10 g/mol
Tesamorelin5,135.86 g/mol

Drawn from the product database. Each measure's bars share one scale.

HGH Fragment 176-191 vs Tesamorelin, compared
What it isA 16-residue peptide: residues 176 to 191 at the C-terminal end of human growth hormone.A 44-residue peptide: an analog of human growth hormone-releasing hormone with an N-terminal trans-3-hexenoyl group.
How they relateDifferent molecules from different parents. HGH Fragment 176-191 corresponds to residues 176 to 191 of human growth hormone. Tesamorelin is an analog of the full 44-residue human growth hormone-releasing hormone.
CAS number66004-57-7218949-48-5
Molecular formulaC78H123N23O22S2C221H366N72O67S
Molecular weight1,799.10 g/mol5,135.86 g/mol
SequenceFLRIVQCRSVEGSCGFtrans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2
Evidence baseNo published study has tested HGH Fragment 176-191 in people. In the literature reviewed for it, the fat-metabolism studies used AOD-9604 or a separate peptide, growth hormone residues 177 to 191. A 1978 study in normal rats did test synthetic 176-191 itself: it briefly raised blood glucose and raised plasma insulin.[7]Human studies, which supported an approval for one indication. A pooled analysis of two phase 3 trials covered 806 randomized participants.[1] Their primary endpoints were imaging surrogates. The trial papers were manufacturer-sponsored.
Regulatory statusNo marketing authorization, and no FDA approval for human use.The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[2][3] That approval is current.
Compared head-to-head?No direct comparison found in PubMed (searched October 2026).[4]
Handling differenceHGH Fragment 176-191 carries two sulfur atoms, enough for an intramolecular disulfide. Tesamorelin's single sulfur is a methionine, which oxidizes on air exposure, and it contains no cysteine.

How HGH Fragment 176-191 and Tesamorelin differ

HGH Fragment 176-191 and Tesamorelin are different molecules from different parents. HGH Fragment 176-191 is the C-terminal 16-residue fragment of human growth hormone, corresponding to residues 176 to 191 of that hormone. Tesamorelin is an analog of the full 44-residue human growth hormone-releasing hormone, with a trans-3-hexenoyl group on its N-terminus.

No published study has tested HGH Fragment 176-191 in people. In the literature reviewed for HGH Fragment 176-191, the fat-metabolism studies used AOD-9604 or a separate peptide, growth hormone residues 177 to 191. Findings produced with either of those are not findings about HGH Fragment 176-191. A 1978 study in normal rats did test synthetic 176-191 itself: it briefly raised blood glucose and raised plasma insulin.[7] The literature reviewed for HGH Fragment 176-191 reports no human safety data. A pooled analysis of Tesamorelin's two phase 3 trials covered 806 randomized participants.[1] In the literature reviewed for Tesamorelin, those trials used imaging surrogates as primary endpoints, not clinical outcomes. The two trial papers and the pooled analysis were manufacturer-sponsored, with sponsor-affiliated co-authors. In the first of the two randomized placebo-controlled phase 3 trials, withdrawal because of an adverse event was higher on Tesamorelin than on placebo.[5]

HGH Fragment 176-191 has no marketing authorization and no FDA approval for human use. The FDA approved tesamorelin acetate in 2010 for one therapeutic indication.[2][3] That approval is current, and it belongs to tesamorelin acetate and that one indication. It is not evidence about HGH Fragment 176-191. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization. That medicine's label lists glucose intolerance or new diabetes among its warnings; HbA1c reached 6.5% or above in 5% of participants on the drug against 1% on placebo.[6]

HGH Fragment 176-191 carries two sulfur atoms, exactly the number an intramolecular disulfide requires. Tesamorelin's single sulfur is a methionine, which oxidizes to a sulfoxide on air exposure. Tesamorelin contains no cysteine, so no disulfide is possible. Tesamorelin may also aggregate on repeated freezing and thawing.

Have HGH Fragment 176-191 and Tesamorelin been compared directly?

No direct comparison of HGH Fragment 176-191 with Tesamorelin was found in a PubMed search run in October 2026.[4] That search covers PubMed only.

Read more on each compound

Frequently Asked Questions

Is HGH Fragment 176-191 the same as Tesamorelin?+

HGH Fragment 176-191 and Tesamorelin are different molecules from different parents. HGH Fragment 176-191 is the C-terminal 16-residue fragment of human growth hormone. Tesamorelin is an analog of the full 44-residue human growth hormone-releasing hormone, with a trans-3-hexenoyl group on its N-terminus.

Is HGH Fragment 176-191 or Tesamorelin approved?+

HGH Fragment 176-191 has no marketing authorization; the FDA approved tesamorelin acetate in 2010 for one therapeutic indication. That approval is not evidence about HGH Fragment 176-191. Tesamorelin acetate is the active ingredient of a prescription medicine sold under another name. The material supplied here is a research-grade preparation, is not that medicine, and holds no marketing authorization.

References

  1. 1
    Pooled analysis of two phase 3 trials, 2010. PMID 20554713.
  2. 2
    US Food and Drug Administration, Center for Drug Evaluation and Research. Approval letter for tesamorelin, 10 November 2010 (Reference ID 2863003).
  3. 3
    US Food and Drug Administration, Drugs@FDA. Approval record whose active ingredient is tesamorelin acetate; marketing status Prescription. Retrieved via api.fda.gov/drug/drugsfda.json on products.active_ingredients.name "TESAMORELIN ACETATE", 3 October 2026.
  4. 4

    PubMed search, 3 October 2026 (records to 2 October 2026)

    1 record; none was a direct comparison of the two compounds.

    Exact query (NCBI E-utilities): ("176-191"[tiab] OR "fragment 176-191"[tiab] OR "frag 176-191"[tiab] OR "hGH fragment"[tiab] OR "hGH 176-191"[tiab] OR "somatotropin (176-191)"[tiab]) AND ("tesamorelin"[tiab] OR "hexenoyl"[tiab] OR "trans-3-hexenoyl"[tiab]) AND ("1800/01/01"[edat] : "2026/10/02"[edat])

    View this search on PubMed
  5. 5
    Phase 3 trial report, 2007. PMID 18057338.
  6. 6
    US Food and Drug Administration. Approved prescribing information for tesamorelin acetate; label version 29 July 2026. Retrieved via openFDA drug/label.
  7. 7
    Rodent study, 1978. PMID 645904. DOI: 10.1152/ajpendo.1978.234.5.E521.
Dr. Martina Rossi, PhD

Reviewed for scientific accuracy

Dr. Martina Rossi, PhD

PhD, Université Grenoble Alpes · Scientific Contributor and Reviewer

Dr. Rossi's doctoral research at Université Grenoble Alpes examined the vascular functions of bone morphogenetic proteins. Her peer-reviewed work spans cell and molecular biology, vascular biology, and gene therapy, in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. She reviews Pure Peptides' product, reference, and research pages for scientific accuracy against the sources they cite.

Reviewed ORCIDGoogle ScholarTeam profile →
Comparison

AOD-9604 vs HGH Fragment 176-191

AOD-9604 and HGH Fragment 176-191 are 16-residue peptides from the C-terminal end of human growth hormone that differ at one position.

Read Comparison
Comparison

AOD-9604 vs Tesamorelin

AOD-9604 is a modified 16-residue peptide from the C-terminal end of human growth hormone; Tesamorelin is a 44-residue analog of human GHRH.

Read Comparison
Comparison

CJC-1295 (No DAC) vs Tesamorelin

CJC-1295 (No DAC) carries four substitutions in human GHRH's first 29 residues; Tesamorelin is an analog of the full 44-residue hormone.

Read Comparison